Real-time multi-spectral imaging for accurate detection of cancerous tissue in endoscopic surgerybroad
rMSI · Horizon Europe grant · 2022-10-01–2024-09-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
Cancer is the leading cause of death in the EU, with 2.7M diagnoses and 1.3M deaths in 2020. Effective removal of cancerous tissue through endoscopic surgery is challenging because of limited visual and absent tactile information, along the limitations of current imaging technologies, which make it difficult for surgeons to differentiate between different types of tissue. For this market, Thericon is developing an rMSI (real-time multispectral imaging) platform providing surgeons with multi-parametric images that help with effective removal of cancerous tissue and reduction of cancer recurrence in patients. The company has developed a prototype for its first product, named rMSI 2, and completed initial validation for bladder cancer applications. Thericon is asking for a 2.5M EIC grant and 5.5M equity funding to complete clinical application pilots, safety tests and CE certification for this product, getting it ready for market launch in 2024.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| THERICON GMBH | DE | coordinator | €2,500,000 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.